PRIMARY INTRAVITREAL BEVACIZUMAB for SUBFOVEAL CHOROIDAL NEOVASCULARIZATION in AGE-RELATED MACULAR DEGENERATION Results of the Pan-American Collaborative Retina Study Group at 12 Months Follow-up

PRIMARY INTRAVITREAL BEVACIZUMAB for SUBFOVEAL CHOROIDAL NEOVASCULARIZATION in AGE-RELATED MACULAR DEGENERATION Results of the Pan-American Collaborative Retina Study Group at 12 Months Follow-up

Author Arevalo, J. Fernando Google Scholar
Fromow-Guerra, Jans Google Scholar
Sanchez, Juan G. Google Scholar
Maia, Mauricio Autor UNIFESP Google Scholar
Berrocal, Maria H. Google Scholar
Wu, Lihteh Google Scholar
Saravia, Mario J. Google Scholar
Costa, Rogerio A. Google Scholar
Institution Clin Oftalmol Ctr Caracas
Hosp Dr Luis Sanchez Bulnes
Universidade Federal de São Paulo (UNIFESP)
Univ Puerto Rico
Inst Cirugia Ocular
Hosp Univ Austral
Hosp Olhos Araraquara
Abstract Purpose: To report the 12-month anatomic and Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin(TM), Genentech Inc., San Francisco, CA) (1.25 mg or 2.5 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.Methods: Sixty-three eyes of 63 consecutive patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration, a mean age of 73.7 +/- 7.5 years and a minimum of 12 months (mean 55.5 +/- 6.2 weeks) of follow-up participated in this interventional retrospective multicenter case series in 7 centers from 6 countries. Patients were treated with at least 1 intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab. Patients underwent Early Treatment Diabetic Retinopathy Study BCVA testing, ophthalmoscopic examination, optical coherence tomography, and fluorescein angiography at baseline and follow-up visits. Repeated measures analysis of variance was used to compare mean values.Results: the mean number of intravitreal bevacizumab injections per eye was 3.5 (range, 1-8). Mean baseline BCVA was 20/320, logarithm of the minimum angle of resolution = 1.2, and mean final BCVA was 20/200, logarithm of the minimum angle of resolution = 1.0 (P < 0.001). Central macular thickness at baseline by optical coherence tomography had a mean of 389.2 +/- 149.6 mu m which was significantly reduced to a mean of 281.0 +/- 96.1 mu m, 268.2 +/- 82.6 mu m, 262.6 +/- 92.3 mu m, and 241.3 +/- 76.7 mu m at 1, 3, 6, and 12 months after initial treatment, respectively (P < 0.0001). Ocular adverse events included transient increased intraocular pressure in 2 (3.1%) eyes, endophthalmitis in 2 (3.1%) eyes, and transient hypotony in 1 eye (1.1%). No systemic adverse events were observed.Conclusion: Primary intravitreal bevacizumab at doses of 1.25 mg or 2.5 mg seems to provide stability or improvement in BCVA, optical coherence tomography, and fluorescein angiography in subfoveal choroidal neovascularization secondary to age-related macular degeneration at 12 months.
Keywords age-related macular degeneration
Avastin
choroidal neovascularization
primary intravitreal bevacizumab
subfoveal
Language English
Date 2008-11-01
Published in Retina-the Journal of Retinal and Vitreous Diseases. Philadelphia: Lippincott Williams & Wilkins, v. 28, n. 10, p. 1387-1394, 2008.
ISSN 0275-004X (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 1387-1394
Origin http://dx.doi.org/10.1097/IAE.0b013e3181884ff4
Access rights Closed access
Type Article
Web of Science ID WOS:000260972600002
URI http://repositorio.unifesp.br/handle/11600/31021

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account